BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Vimal Mehta - Founder & CEO Richard Steinhart - SVP & CFO Matt Wiley - SVP & Chief Commercial Officer Robert Risinger - Chief Medical Officer, Neuroscience Frank Yocca - Chief Scientific Officer Conference Call Participants Gregory Harrison - Bank of America Colin Bristow - UBS Sumant Kulkarni - Canaccord Raghuram Selvaraju - H.C. Wainwright Yatin Suneja - Guggenheim Securities Samir Dev ...

record net prepaid or accrued expense relating to these costs. Such estimates are subject to change as additional information becomes available. The Company expenses research and development costs as incurred. Costs related to filing and pursuing patent applications are recorded in Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations and are expensed as incurred since recoverability of such expenditures is uncertain. ● Level 2: Directly or indirectly observable ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Rob Risinger - Chief Medical Officer, Neuroscience Matt Wiley - Chief Commercial Officer Richard Steinhart - Chief Financial Officer Conference Call Participants Robyn Karnauskas - Truist Securities Mary Kate - Bank of America Colin Bristow - UBS Yatin Suneja - Guggenheim Partners Sumant Kulkarni - Canaccord Genuity Ram Selvaraju - H.C. Wainwri ...

Contractual Obligations and Commitments In April 2022, the Company signed a commercial supply agreement that requires minimum annual payments for the first three years of the agreement that in aggregate total $10,000 for the three-year period and the minimum commitment for 2023 is $3,000. In February 2022, we signed a distribution agreement with a third-party to distribute product related to BXCL501 in the U.S. The distributor will be paid defined fees for its services under the agreement, which can be term ...

14 the FDA, as well as by the European Medicines Agency ("EMA"), to fulfill potential commitments to study the effects of BXCL501 in pediatric patients ages 13-17 with schizophrenia and ages 10-17 with bipolar disorders. Enrollment of patients with schizophrenia, schizoaffective disorder, bipolar I, and bipolar II disorder is ongoing in this multisite, double-blind, placebo-controlled parallel group trial. Approximately 40% of the 150 total subjects have been enrolled in the U.S. and several European sites ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2022 Earnings Conference Call March 9, 2023 8:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Matt Wiley - Chief Commercial Officer Richard Steinhart - Chief Financial Officer Rob Risinger - Chief Medical Officer, Neuroscience Vincent O’Neill - Chief R&D Officer of OnkosXcel Therapeutics Conference Call Participants Colin Bristow - UBS Robyn Karnauskas - Truist Securities Greg Harrison - Bank of America Graig Suvannavejh - Mizuho Secu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38410 BioXcel Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-13867 ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Matt Wiley - Chief Commercial Officer Richard Steinhart - Chief Financial Officer Rob Risinger - Chief Medical Officer, Neuroscience Vincent O’Neill - Chief Medical Officer, Oncology Conference Call Participants Greg Harrison - Bank of America Colin Bristow - UBS Yatin Suneja - Guggenheim Partners Graig Suvannavejh - Mizuho Securities Ra ...

| --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------|-------|--------------| | | | | | | | | | | | | | | | | | ® AI-Driven Transformative Medicines in Neuroscience and Immuno-oncology | | | | | | | | September 2022 | | | | BioXcel Therapeutics \| 555 Long Wharf Drive, 12th Floor \| New Haven, CT 06511 \| www.bioxceltherapeutics.com | | NASDAQ: BTAI | Forward-Looking Statements This presentation includes "forward-looking ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38410 BioXcel Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1386754 (S ...